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Background Patient-reported outcomes (PROs) are particularly
relevant in influenza vaccine trials in the elderly where reduction in
symptom severity could prevent illness-related functional impair-
ment.
Objectives To evaluate PROs in people aged ≥65 years receiving
two different vaccines.
Methods This was a phase III, randomised, observer-blind study
(NCT00753272) of the AS03-adjuvanted inactivated trivalent split-
virion influenza vaccine (AS03-TIV) versus non-adjuvanted vaccine
(TIV). Using the FluiiQ questionnaire, symptom (systemic,
respiratory, total) and life impact (activities, emotions,
relationships) scores were computed as exploratory endpoints, with
minimal important difference (MID) in influenza severity between
vaccines considered post-hoc as >7%. Vaccine efficacy of AS03-TIV
relative to TIV in severe influenza (hospitalisation, complication,
most severe one-third of episodes based on the area under the curve
for systemic symptom score) was calculated post-hoc. The main
analyses (descriptive) were conducted in the according-to-protocol
cohort (n = 280 AS03-TIV, n = 315 TIV) for influenza confirmed
by culture or reverse transcriptase polymerase chain reaction.
Results Mean systemic symptom, total symptom and impact on
activities scores were lower with AS03-TIV versus TIV. Mean
respiratory symptom, impact on emotions and impact on
relationships scores were similar. Influenza tended to be less severe
with AS03-TIV, but the MID was reached only for impact on
activities (mean 90%). Relative vaccine efficacy in severe influenza
was 2938% (95% CI: 760–4602).
Conclusions AS03-TIV had advantages over TIV in impact on
systemic symptoms and activities as measured by the FluiiQ in
elderly people. Higher efficacy of AS03-TIV relative to TIV was
shown for prevention of severe illness.
Keywords AS03-adjuvanted vaccine, elderly, FluiiQ, influenza,
patient-reported outcomes.
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Introduction
The burden of hospitalisation and death in the elderly due to
seasonal influenza is high,1–3 and vaccination against
seasonal influenza is recommended routinely for individuals
aged over 65 years in many countries. However, it is well
recognised that the immune response to vaccination is lower
in the elderly than in younger adults, with a corresponding
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decrease in vaccine effectiveness.4,5 One of the strategies to
achieve a better immune response in the elderly is the use of
adjuvants in vaccine formulations. The AS03 Adjuvant
System is a tocopherol-based oil-in-water emulsion that
has been approved for use in pandemic influenza vaccines in
many countries. Studies have shown that vaccines formulated
with AS03 are highly immunogenic against H5N1 avian
strains and the human pandemic influenza H1N1 strain in
elderly and non-elderly adults.6–10 A community-based case–
control study of the MF59-adjuvanted trivalent seasonal
vaccine has also shown benefit in the elderly versus a non-
adjuvanted vaccine.11 Thus, adjuvanted vaccines provide a
potential approach to reduce the incidence and severity of
influenza in the elderly.
Patient-reported outcomes (PROs) have become recogni-
sed as important endpoints in clinical trials in many
therapeutic areas, and guidelines for their development and
use have been issued by the US Food and Drug Adminis-
tration (FDA).12 However, clinical trials of influenza vaccines
usually focus on prevention of infection. In the elderly,
reduction in disease severity of breakthrough cases may be a
more realistic goal and would represent a clinically signif-
icant achievement. Disease severity outcomes are best
measured by PROs. A new instrument, the Influenza
Intensity and Impact Questionnaire (FluiiQ), was recently
developped to document PROs in influenza.13 The FDA has
strict criteria governing the development and validation of
PROs, and the FluiiQ is the only questionnaire developed for
influenza to meet them. Development of the FluiiQ took
place over three influenza seasons including data prospec-
tively obtained from 25 sites across the USA.13
The present study evaluated a seasonal AS03-adjuvanted
inactivated trivalent split-virion influenza vaccine (AS03-
TIV) versus a non-adjuvanted trivalent vaccine (TIV) in an
elderly population. Data from this study have been reported
previously, showing that fewer participants receiving the
AS03-TIV were infected with influenza A and/or B compared
with TIV, although superiority of the AS03-TIV was not
established.14 Because the primary efficacy endpoint of the
study was not demonstrated, development of the AS03-TIV
has been discontinued. Here, we describe PROs collected
during the study.
Methods
This was a phase III, randomised, observer-blind study
(NCT00753272). Its main aim was to assess the relative
efficacy of AS03-TIV versus TIV for the prevention of
confirmed influenza A and B. The present paper focuses on
PROs evaluated during the study. The trial was approved by
relevant independent ethics committees or institutional
review boards in each country, and was conducted in
accordance with the Declaration of Helsinki, the Interna-
tional Conference on Harmonisation Good Clinical Practice
guidelines, and regulatory requirements of participating
countries. All participants provided written informed con-
sent.
Participants
Participants were recruited from Belgium, Canada, Czech
Republic, Estonia, France, Germany, Mexico, Norway,
Poland, Romania,1 Russia, Taiwan, the Netherlands, the
United Kingdom and the USA and vaccinated during the
usual Northern Hemisphere vaccination campaigns in the
2008/2009 and 2009/2010 influenza seasons. Because of the
unexpected high circulation of the pandemic H1N1 strain
during the 2009/2010 season and very few cases of seasonal
influenza A and/or B, PROs were not analysed for the 2009/
2010 season. Data are reported only for the 2008/2009
season. The first participant was vaccinated on 15 September
2008 and the last on 7 November 2008.
Participants were aged ≥65 years and lived in the com-
munity or in a retirement home that allowed mixing in the
community. Participants who were in hospital, bedridden or
who had an acute illness (moderate or severe illness with or
without fever) were excluded. Other exclusion criteria
included receipt of any influenza vaccine after February
2008 or vaccination in the previous 3 years with an
investigational adjuvanted seasonal or pandemic influenza
vaccine.
Study design
Participants were randomised to receive AS03-TIV (07 ml)
or TIV (05 ml; FluarixTM) vaccines, both manufactured by
GlaxoSmithKline Vaccines. Both vaccines contained 15 lg
haemagglutinin antigen per recommended influenza strain
for the 2008/2009 season: A/Brisbane/59/2007 (H1N1),
A/Uruguay/716/2007 (H3N2), B/Brisbane/3/2007 (B/Yamag-
ata). The Adjuvant System contained 593 mg a-tocopherol
and squalene in an oil-in-water emulsion (AS03B formula-
tion). A blocking scheme was used to randomise participants
to the AS03-TIV and TIV groups with a 1:1 ratio.
Randomisation was performed by the study sponsor and
treatment allocation at each site was implemented using an
internet-based system. Within each age stratum (65–74 years
or ≥75 years), the randomisation algorithm used a
1There are concerns regarding the integrity of study data from a
single study site in Romania which enrolled 102 subjects in the trial.
At the time the concerns arose, the analyses for the study had already
been completed. Because evaluation of data from this site did not
reveal irregularities when compared with overall study data and
because GSK has no current plans to use the data from the study in
support of any regulatory filings, data from this site were not
excluded from the analyses reported in this manuscript.
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minimisation procedure accounting for study centre and
whether participants lived in a retirement home. Participants
remained in the same treatment group in both influenza
seasons. The vaccines were administered in the deltoid
muscle of the non-dominant arm. Because they were slightly
different in appearance, they were administered by personnel
who took no further part in the study. Observers and
participants were blind to vaccine allocation.
Surveillance and identification of influenza-like
illness and influenza
Active surveillance was performed from 15 November 2008
until the week of 30 April 2009, the most likely period of
influenza virus circulation in the Northern Hemisphere.
Participants were contacted biweekly, or weekly (between the
weeks of 15 December and 31 March), and monitored for
influenza-like illness (ILI), pneumonia, new onset or wors-
ening congestive heart disease, myocardial infarction, stroke,
respiratory disease causing hospitalisation, hospitalisation or
urgent care visit, and serious or specified adverse events. In
addition, participants were instructed to inform the study
centre if they developed any of these events. ILI was defined
as the simultaneous occurrence of at least one systemic
symptom (headache, fatigue, myalgia, feverishness or fever
[oral temperature ≥375°C]) and at least one respiratory
symptom (nasal congestion, sore throat, cough, dyspnoea,
sputum production or wheezing).
Nasal and throat swab specimens were collected within
5 days of the onset of ILI symptoms for confirmation of
influenza virus A or B via reverse transcriptase polymerase
chain reaction (RT-PCR) or via culture (Rhesus Monkey
Kidney or Madin–Darby Canine Kidney tissue cultures) as
previously described.15 The influenza peak season was
defined for each participating country by an adjudication
committee based on national surveillance and study data.
Only cases with matching or drift influenza strains relative to
the vaccine strains were included in the vaccine efficacy
analysis, as a protocol amendment excluded the pandemic
H1N1 strain from influenza-confirmed cases. However, the
few pandemic H1N1 cases occurring during the 2008/2009
season were included in the PRO analysis.
Study endpoints – patient-reported outcomes
Participants who experienced an ILI episode between 15
November 2008 to the end of the surveillance period and
who provided a nasal or throat swab completed an ILI
booklet that included the FluiiQ.13 The FluiiQ questionnaire
was completed daily from the onset of the ILI episode until
15 days post-ILI onset. The FluiiQ consisted of five scales:
systemic symptoms, respiratory symptoms, impact on daily
activities, impact on emotions and impact on relationships.
Each scale comprised 3–7 items with a 4-point Likert scale
response option (0–3) where 0 indicates the absence of
symptoms or absence of impact and 3 indicates highest
severity of symptoms or highest impact.
Statistics
All PROs were exploratory endpoints. Sample size calcula-
tions were based on the primary endpoint and are described
elsewhere.14 SAS 9.2 was used for statistical analysis.
Analysis of PROs
Only ILI cases that occurred at least 2 weeks post-vaccination
were included in the analysis to allow sufficient time for
participants to mount an antibody response. Analysis of
PROs was performed in the one-dose according-to-protocol
(ATP) efficacy cohort which included all participants who
received their first vaccine dose according to their random
assignment, complied with the protocol and started their first
active surveillance period (from 15 November 2008). In
addition, participants who received their first vaccine dose
after 1 November 2008 must not have discontinued the study
within 2 weeks of vaccination to ensure at least 2 weeks of
follow-up and sufficient time to mount an antibody response
as stated above.
Within the one-dose ATP efficacy cohort, three subcohorts
of participants who reported PROs were considered: (i)
influenza-confirmed: all participants whose selected ILI
episode was confirmed for influenza by PCR or culture and
started within the surveillance period; (ii) ILI within peak
season: all participants who experienced their selected ILI
episode within the peak influenza season (both episodes
confirmed and not confirmed for influenza by PCR or
culture were included); (iii) influenza-negative: all partici-
pants whose selected ILI episode started outside the peak
influenza season and was not confirmed for influenza by PCR
or culture.
After computation of the FluiiQ scores, only one ILI
episode per participant was considered in the analysis. If a
participant experienced more than one influenza-confirmed
ILI episode, the first episode was selected for the analysis. If a
participant experienced several non-confirmed influenza ILI
episodes, the episode included was selected as follows: (i)
episode(s) for which a total symptom score was available for
≥5 days, with ≥1 day assessed during the first 5 days of the
ILI; (ii) episode(s) that started during the peak influenza
season; and (iii) one episode randomly selected. Only
participants whose selected ILI episode had an evaluable
PRO (≥5 days with an available total symptom score and ≥1
of these days assessed during the first 5 days of the ILI) were
taken into account in the analysis.
Computation of FluiiQ scores
The FluiiQ was recorded daily. Each scale score was
calculated by summing the responses to non-missing items
recorded by individuals. The item response options ranged
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from 0 (no symptom/impact) to 3 (highest symptom
intensity/impact). For each scale, the score was standardised
to extend between 0 and 3 to be consistent with the response
options and assist with interpretation of scores.
A score was considered as missing if the number of
missing values on a particular scale was greater than or equal
to half of the total number of items on a scale. Some missing
scores were replaced by zero when at least one item on the
scale had been recorded and the subject had indicated that
they had ceased to complete the questionnaire because their
symptoms had disappeared (applicable for all last days from
which all items are equal to zero or missing and until Day 14)
or had completed the questionnaire only on days when they
experienced symptoms (applicable for all days from which all
items are equal to zero or missing). Further imputation of
missing values was a composite method based on (i) the last-
observation-carried-forward method when zero was the last
available score and (ii) multiple imputation using the
Expectation-Maximisation algorithm (10 iterations of plau-
sible values).16,17
Four derived variables based on each scale were
calculated to evaluate the severity of clinical episodes: (i)
maximum score throughout the 15-day follow-up period;
(ii) area under the curve (AUC) from Day 0 to Day 14;
(iii) AUC from Day 0 to Day 7; (iv) AUC from Day 0 to
Day 4. The percentage difference between the TIV and
AS03-TIV for the mean of the maximum score was
calculated post-hoc as the absolute percentage change
across the scale (0–3). In the absence of a gold standard in
this field and to provide a benchmark for comparison, a
minimal important difference (MID) was set at >7%.18–20
In addition, the time in days from Day 0 to total symptom
score <05 was calculated to estimate the duration of
clinical episodes.
Continuous parameters are presented using descriptive
statistics (mean, standard error, minimum and maximum).
No inferential analysis was performed. The analysis was
based on multiple imputation, so 95% confidence intervals
(CIs) were calculated according to the method of Rubin
(procedure MIANALYZE).
Relative vaccine efficacy in severe illness
A post-hoc analysis evaluating severe influenza-confirmed
episodes and severe ILI episodes was performed. Severe
episodes were defined as those resulting in hospitalisation or
a complication (death, pneumonia, myocardial infarction,
stroke, congestive heart failure) or according to AUC (Day
0–Day 7) for the systemic and total symptom scores. For the
AUC definition, one third of all episodes (those with the
highest AUC) were considered to be severe. Episodes with no
associated hospitalisation or complication, and with no or
insufficient PRO information, were excluded from this
analysis.
Vaccine efficacy of the AS03-TIV relative to the TIV in
prevention of severe ILI and severe confirmed influenza A
and/or B infection within the one-dose ATP efficacy cohort
was calculated. Relative efficacy and 95% CIs were estimated
by fitting a proportional hazards regression on the time-to-
event, taking into account age (65–74 versus ≥75 years) and
regional differences in attack rates (AR) (the Netherlands,
Poland and Czech Republic [AR: 265–344%]; Belgium, UK,
Norway, France, Germany and Russia [AR: 128–184%];
Canada, Romania, Mexico, Estonia, US and Taiwan [AR:
040–110%).
Results
Participants and compliance with ILI booklet
completion
A total of 43 802 participants were enrolled, and 43 695 were
vaccinated (21 893 and 21 802 in the AS03-TIV and TIV
groups, respectively). A total of 664 and 718 participants in
the AS03-TIV and TIV groups, respectively, withdrew from
the study during the first year. The one-dose ATP efficacy
cohort included 21 573 participants in the AS03-TIV group
and 21 482 participants in the TIV group. Reasons for
withdrawal and exclusion from the cohort are reported
elsewhere.14 The mean age at first vaccination was 735 years
in both vaccine groups, and 57% of participants in both
groups were women. Most participants (86%) were of
Caucasian origin.
Participants were included in the PRO analysis if they
experienced an ILI and had an evaluable PRO for the selected
episode. The number of participants in the AS03-TIV and
TIV groups, respectively, for each subcohort was 280 and 315
(influenza-confirmed), 949 and 963 (ILI within peak season)
and 960 and 982 (influenza-negative). Only one participant
reported two influenza-confirmed episodes (one influenza A
and the other influenza B), and only the first episode
(influenza B) was taken into account in the analysis.
Compliance with completion of the ILI booklet was
generally good, with similar percentages of participants
completing at least 50% of the ILI booklet in both vaccine
groups: 825% (AS03-TIV) and 833% (TIV) in the influ-
enza-confirmed subcohort, 898% (AS03-TIV) and 911%
(TIV) in the ILI within peak season subcohort, and 858%
(AS03-TIV) and 827% (TIV) in the influenza-negative
subcohort.
Influenza symptom scores
In the influenza-confirmed subcohort, the mean total
symptom score and the mean systemic symptom score were
lower in the AS03-TIV group than in the TIV group,
particularly between Days 0 and 3, although the 95% CIs
overlapped (Figure 1). The mean difference between groups
persisted for approximately 1 week. The respiratory
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symptom score was similar in both groups (Figure 1). In the
ILI within peak season subcohort and the influenza-negative
subcohort, all symptom scores were similar in both vaccine
groups (Figures S1 and S2). All three symptom scores were
higher in the influenza-confirmed subcohort compared with
the other two subcohorts (Figure 1; Figures S1 and S2).
In all three subcohorts, the observed mean severity of ILI
episodes was similar or less in the AS03-TIV group compared
with the TIV group, based on the maximum score and AUC
(Day 0–Day 14) for each symptom score (Table 1). Differ-
ences in symptom scores between the AS03-TIV and the TIV
were most marked in the influenza-confirmed subcohort;
however, none reached the MID of 7% (Table 1). Results
were similar for severity based on AUC (Day 0–Day 4) and
AUC (Day 0–Day 7), with similar or lower scores in the
AS03-TIV group versus the TIV group (data not shown).
The duration of ILI episodes using the total score tended
to be shorter in the AS03-TIV group. In the AS03-TIV and
TIV groups, respectively, the duration was 748 (standard
error 0287) and 784 (0244) days in the influenza-
confirmed subcohort, 640 (0139) and 667 (0137) days in
the ILI within peak season subcohort, and 635 (0140) and
636 (0140) days in the influenza-negative subcohort.
There was no difference in severity and duration of ILI
episodes in participants aged ≥75 years compared with those
aged 65–74 years (data not shown). The vaccines had a
similar impact on symptom severity in both age groups (data
not shown).
Impact on life scores
In the influenza-confirmed subcohort, the mean impact on
daily activities score was lower in the AS03-TIV group,
particularly during the first week (Figure 2). However, the
95% CIs did not overlap only on Day 0 and Day 1. The
impact on emotions score and impact on relationships score
were similar in both vaccine groups (Figure 2). As seen with
symptom scores, life impact scores were similar in both
vaccine groups in the ILI within peak season subcohort and
the influenza-negative subcohort (Figures S3 and S4). All
three life impact scores were higher in the influenza-
confirmed subcohort compared with the ILI within peak
season and influenza-negative subcohorts, particularly for
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Figure 1. Total symptom, systemic symptom and respiratory symptom scores in the influenza-confirmed subcohort.
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the impact on daily activities score (Figure 2; Figures S3 and
S4).
The severity of ILI episode tended to be less in the AS03-
TIV group compared with the TIV group. Again, differences
were most marked in the influenza-confirmed subcohort;
here, the difference between the AS03-TIV and TIV groups in
severity based on the impact on daily activities score reached
90% (greater than the MID of 7%) (Table 1).
The impact of influenza was greater for all scores in the
≥75 year age group than in the 65–74 year group; however,
there was no difference between the vaccines when stratified
by age (data not shown).
Relative vaccine efficacy in severe illness
A post-hoc analysis evaluated relative vaccine efficacy of the
AS03-TIV compared with the TIV for prevention of severe
Table 1. Severity of ILI episode based on the mean of the maximum scores and the AUC from Day 0 to Day 14
Score
Subcohort
Confirmed influenza ILI within peak season Influenza-negative
AS03-TIV TIV
Difference
(%) AS03-TIV TIV
Difference
(%) AS03-TIV TIV
Difference
(%)
Total symptom
Max
score
(SE)
150 (0043) 164 (0040) 47 133 (0021) 138 (0020) 17 132 (0021) 136 (0022) 13
AUC
(SE)
912 (0421) 981 (0392) – 776 (0194) 810 (0190) – 800 (0204) 816 (0205) –
Systemic symptom
Max
score
(SE)
144 (0049) 158 (0047) 47 124 (0023) 128 (0023) 13 120 (0023) 125 (0024) 17
AUC
(SE)
788 (0447) 861 (0420) – 658 (0199) 693 (0198) – 669 (0206) 688 (0211) –
Respiratory symptom
Max
score
(SE)
178 (0045) 190 (0040) 40 166 (0023) 172 (0022) 20 174 (0023) 174 (0023) 00
AUC
(SE)
1210 (0446) 1270 (0416) – 1053 (0231) 1086 (0219) – 1108 (0241) 1121 (0238) –
Impact on daily activities
Max
score
(SE)
127 (0065) 154 (0062) 90 099 (0030) 108 (0031) 30 097 (0030) 100 (0030) 10
AUC
(SE)
658 (0520) 803 (0513) – 470 (0206) 548 (0232) – 481 (0212) 490 (0223) –
Impact on emotions
Max
score
(SE)
089 (0054) 102 (0057) 43 075 (0025) 083 (0026) 27 077 (0026) 082 (0026) 17
AUC
(SE)
454 (0410) 539 (0473) – 378 (0190) 423 (0202) – 389 (0189) 410 (0195) –
Impact on relationships
Max
score
(SE)
067 (0050) 074 (0051) 23 052 (0022) 055 (0023) 10 053 (0022) 055 (0023) 07
AUC
(SE)
356 (0404) 399 (0419) – 264 (0164) 294 (0174) – 269 (0161) 290 (0171) –
AUC: area under the curve; SE: standard error.
The percentage difference is calculated as the absolute percentage change across the scale (0–3): (TIV minus AS03-TIV) divided by 3*100. A difference
of >7% was regarded as the MID.
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influenza-confirmed and severe ILI episodes. There were 91
severe influenza-confirmed episodes in the AS03-TIV group
compared with 128 episodes in the TIV group, with a relative
vaccine efficacy of 2938% (95% CI: 760–4602) based on the
definition using the systemic symptom score (Figure 3). The
corresponding relative vaccine efficacy in severe ILI was 915%
(104–1831). Based on the definition using the total symp-
tom score, relative vaccine efficacywas 2903% (698–4585) for
severe influenza-confirmed episodes and 1036% (033–1939)
for severe ILI episodes (Figure S5). Most severe influenza-
confirmed episodes were caused by the A/H3N2 strain (767%
in the AS03-TIV group and 841% in the TIV group).
Discussion
To our knowledge, this is the first clinical efficacy trial of an
influenza vaccine to report PROs due to the previous lack of
a valid and reliable measure for influenza. Currently,
complete prevention of influenza illness through vaccination
appears to be unachievable, and thus, the primary aim of
vaccination in elderly people may lie in the prevention of
severe illness and reduction in morbidity and burden of
influenza-associated complications. Such outcomes are
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ideally measured by PROs, which are relevant in the real-life
setting and capture the experience of patients.
The efficacy of influenza vaccination is currently under
question.21 Novel endpoints such as PROs and severe illness
capture aspects of influenza that are relevant from both a
clinical and public health perspective. It is therefore impor-
tant that vaccine trials assessing potentially more efficacious
influenza vaccines include such endpoints, as trials based
solely on conventional endpoints might underestimate the
value of vaccination. This may be particularly important in
the elderly, because if an older person becomes bedbound or
housebound for a period, they may lose function and
independence which is never regained.22 Our analysis
indicates that inclusion of PROs provides an additional
dimension to clinical trials over and above traditional
efficacy measures that are important to include in future
studies.
The study showed a difference in favour of the AS03-TIV
for the systemic symptom score and impact on daily activities
score in the influenza-confirmed subcohort. The vaccines
had a similar impact with respect to the respiratory symptom
score, the impact on emotions score and the impact on
relationships score. Likewise, the vaccines had a similar
impact in the two other subcohorts evaluated, the ILI within
peak season subcohort and the influenza-negative subcohort.
Influenza was generally more severe in the TIV group than in
the AS03-TIV group in all subcohorts and as measured by all
symptom and impact on life scores. However, only the
impact on daily activities score in the influenza-confirmed
subcohort reached the benchmark MID of 7% between the
TIV and AS03-TIV. The duration of ILI episodes tended to
be shorter in the AS03-TIV group, although the difference
between vaccines was not large.
The FluiiQ revealed the largest difference between the
vaccines in the influenza-confirmed subcohort, which is
expected as the FluiiQ was designed to be sensitive to
influenza-specific outcomes,13 and the vaccine is effective
exclusively against the influenza virus. By definition, all
participants in the influenza-confirmed subcohort were
infected with the influenza virus, whilst many participants
in the other subcohorts could have had ILI caused by other
viruses such as respiratory syncytial virus. It has been shown
previously that the mean scores for severity of symptoms as
measured by the FluiiQ questionnaire are higher in con-
firmed influenza compared with ILI, suggestive of more
severe symptoms in the former.13
The post-hoc analysis of relative vaccine efficacy against
severe influenza-confirmed episodes demonstrated a differ-
ence in efficacy in favour of the AS03-TIV. We chose to
evaluate vaccine efficacy of the AS03-TIV relative to the TIV
in severe confirmed influenza because of the importance of
severe illness in older adults where the community burden
associated with death and hospitalisation is high.1–3 We
defined severe illness as a hospitalisation, complication
(including death) or illness with an AUC for the systemic
symptom score in the top one-third of all episodes. In an
attempt to provide an overall perspective, we did the same
analysis defining severe illness as a hospitalisation, compli-
cation or illness as measured by the FluiiQ total symptom
score, and found similar results. It should be noted that
calculation of a total score encompassing the systemic and
respiratory items is not recommended because these have
been found to be empirically different constructs, suggesting
that they should not be summed.13 The finding in favour of
the AS03-TIV in severe confirmed influenza gives another
perspective in addition to the classical influenza-confirmed
endpoint. Identification of vaccines that reduce severe
influenza in the most vulnerable members of society is
expected to have a positive impact on mortality and
morbidity in these important target groups.
The possible mechanism for the findings in favour of the
AS03-TIV must remain speculative, especially in view of the
fact that analysis of the PROs was not inferential, the analysis
of relative vaccine efficacy in severe illness was conducted
post-hoc, and the primary efficacy endpoint of the study was
not demonstrated. Higher antibody titres induced by the
adjuvanted vaccine are likely to provide part of the expla-
nation, but it should be noted that titres were measured only
in subgroups of participants and therefore the antibody
profile of all participants is unknown. It may also be possible
that memory B-cell response may have been higher in
participants receiving AS03-TIV, but this was not measured
in the study. Cell-mediated immunity is likely to also play a
role; indeed, T-cell responses have been shown to be better
correlates of influenza vaccine protection in the elderly
compared with antibody responses.23
The study had several strengths and limitations. A key
strength was the use of the validated FluiiQ for measurement
of PROs. Until now, influenza trials have been unable to
study PROs comprehensively and reliably because of the lack
of a validated measure to study the impact of influenza
infection. The availability of the FluiiQ, a disease-specific
measure of influenza, opens up the possibility to study the
impact of vaccination on outcomes. In this study, we
obtained a high response rate to the questionnaire in this
elderly population, suggesting that the FluiiQ was easier to
apply than perhaps initially believed. There are anecdotal
reports from studies of anti-influenza treatments that the
questionnaire actually helps to retain participants in a trial
because they are routinely reminded of the trial through
completing the questionnaire. The role of PROs in improv-
ing the quality of influenza research thus seems to be
supported.
A limitation of our analysis of relative vaccine efficacy is
that it is a post-hoc exploratory analysis not guided by
specific hypotheses, therefore caution must be exercised in
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making conclusions about the efficacy of the AS03-TIV
relative to the TIV in severe illness. Establishment of valid
MIDs in PRO research remains problematic, and further
studies are required to develop clinical benchmarks in
support of what magnitudes of improvement in PROs are
relevant in the influenza setting from both the clinical and
public health perspectives.18 A further limitation is that the
most severe cases might have been excluded from the analysis
because they failed to complete the FluiiQ. In addition, we
did not evaluate correlation of PROs with viral load.
Strengths, limitations and generalisability of the trial as a
whole have been previously described.14 The primary analysis
illustrated a number of important lessons for the conduct of
comparative vaccine trials in influenza.14
In conclusion, our exploratory analysis showed that the
AS03-TIV has some advantages over the TIV in reduction of
the impact of influenza on daily activities as measured by the
FluiiQ, as well as in prevention of severe illness. Notwith-
standing the caveats regarding efficacy, the results suggest
that PRO evaluation and the impact of vaccination on
disease severity and confirmed influenza should be the key
components of future vaccine trials.
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